Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy
Immunostimulatory therapies that activate immune response pathways are of great interest for overcoming the immunosuppression present in advanced tumors. Agonistic anti-CD40 antibodies and CpG oligonucleotides have previously demonstrated potent, synergistic anti-tumor effects, but their clinical us...
| Päätekijät: | , , |
|---|---|
| Muut tekijät: | |
| Aineistotyyppi: | Artikkeli |
| Kieli: | en_US |
| Julkaistu: |
Elsevier
2015
|
| Linkit: | http://hdl.handle.net/1721.1/99424 https://orcid.org/0000-0002-4267-237X |